AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 272 min read$MED

Medifast Inc (MED) (Q3 2026) Earnings Call Highlights: Revenue Stabilizes Near $75 Million

Medifast Inc (MED) reported Q3 2026 revenue of $72M, down 19.4% YoY, with revenue stabilizing near $75M for four quarters. CEO Nicholas Johnson highlighted high engagement and productivity among coaches, despite a decline in active coach numbers. The company expects continued productivity growth and cost efficiencies. Q4 revenue guidance is $55M-$75M, with EPS of $0-$0.25. Medifast has $172.5M in cash and no debt, with a target of profitability in Q4 2026.

Original reporting
finance.yahoo.com
Published Oct 27, 2026, 5:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 5:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Medifast Inc (MED) (Q3 2026) Earnings Call Highlights: Revenue Stabilizes Near $75 Million — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$MEDBearishMed
01

Why it matters

The disclosed revenue decline and guidance set expectations for the next quarter, influencing investor sentiment.

02

Market read

First‑time Q3 results and guidance for Medifast; material for traders tracking health‑coach stocks.

03

What to watch

AI‑driven cost reductions and new Trilivy brand adoption may improve margins later in 2026.

Relevance 7/10Novelty 7/10Timing: after earnings release, Q3 2026

Background

Medifast discussed operational changes, GLP‑1 competition, and AI cost initiatives during its Q3 earnings call.

Company-level read

Ticker impact

$MEDBearishHigh confidence
Context

Q3 2026 earnings disclosed revenue of $72M (down 19.4% YoY) and provided Q4 guidance of $55M‑$75M revenue and EPS $0‑$0.25.

Expected impact

likely downside as investors price in lower revenue and modest guidance

Evidence & confidence

First‑time disclosure of Q3 results and guidance; the revenue drop and low guidance are material for a mid‑cap weight‑loss company.

Market effects

Sector

Weight‑loss and health‑coach sector may see broader scrutiny as GLP‑1 competition intensifies.

Regional

U.S. consumer health segment could face margin pressure.

Global

Limited; impact confined to Medifast and peers in the diet‑program space.

Counterpoint

What could challenge this read

The debt‑free balance sheet and high coach productivity could enable a turnaround, supporting a short‑term bounce.

Key entities

  • company
    Medifast Inc

    U.S. weight‑loss program provider (ticker MED).

  • executive
    Nicholas Johnson

    CEO of Medifast.

  • executive
    James Maloney

    CFO of Medifast.

Read at source← All news

StoryMedifast reports Q3 2026 loss, coach decline and sets Q4 profitability target

Also covered by

5 outlets

Related articles

OCT 28
$MEDMed

5 insightful analyst questions from Medifast’s Q3 earnings call

Medifast's Q3 revenue exceeded expectations but declined year-over-year. Management cited the Trilogy brand's success and improved coach productivity. Analysts questioned coach engagement, competition with GLP-1 medications, and cost reduction. The stock is trading at $12.50. Key focus areas include Trilogy adoption, coach productivity, and cost efficiencies.

financialcontent.com2 min
OCT 27
$MEDHigh

Why Medifast (MED) stock is trading up today

Medifast (MED) shares rose 6.2% after Q3 results beat expectations, with adjusted EBITDA of $1.9M. CEO Nick Johnson highlighted new product launches and guidance for Q4 revenue of $55M-$75M. Full-year revenue is expected at $280M-$300M, with a GAAP loss of $1.80-$2.05 per share.

financialcontent.com2 min
OCT 26
$MEDMed

Medifast, Inc. Q3 2026 Earnings Call Summary

Medifast (MED) reported a 19.4% revenue decline in Q3 2026, attributing it to lower active coach counts due to GLP-1 medication adoption. The company is transitioning to a metabolic health system called Trilogy and implementing cost-cutting measures. Q4 2026 revenue is expected between $55M and $75M, with a focus on profitability and long-term growth. Management sees GLP-1s as a catalyst for consumer interest rather than a direct threat.

finance.yahoo.com2 min
OCT 26
$MEDMed

What Medifast (MED) Said on Its Q3 Earnings Call

Medifast (MED) reported a Q3 operating loss of $19.4M, including restructuring charges. The company introduced new products and highlighted GLP-1 medications' impact on client conversations. Medifast forecasts Q4 revenue of $55M-$75M and full-year 2026 revenue of $280M-$300M, aiming for profitability in Q4.

finance.yahoo.com2 min